Cancer clinical trials in the region Occitanie
208 currently recruiting clinical trials
If you are a doctor and would like find matching clinical trials for you patients, create an account or log in
If you are a patient and would like to know if you may participate in a clinical trial, please consult your doctor so that he can send your file to a matching trial
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
EGFR
Targeted therapy
Systemic Treatment-Naive
Janssen
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
EGFR
None
Systemic Treatment-Naive
Janssen
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Non-squamous NSCLC
Locally Advanced
EGFR
None
Chemotherapy
Radiotherapy
AstraZeneca
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Localized
ALK
None
Systemic Treatment-Naive
Surgery
Hoffmann-La Roche
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Localized
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
None
Systemic Treatment-Naive
ALK
EGFR
Bristol-Myers Squibb
Early Access
Lung cancer
SCLC (Small Cell Lung Cancer)
Localized
Locally Advanced
None
Chemotherapy
Radiotherapy
Chemotherapy
Radiotherapy
AstraZeneca
Phase 3
Bladder / Urinary Tract / Urethral cancer
#NCT06319820
Non-invasive bladder cancer
Localized
FGFR
None
1
2
3 or more
Centre Hospitalier Universitaire de Toulouse (Toulouse), Clinique La Croix du Sud - Ramsay Santé (Quint-Fonsegrives)
Janssen
Phase 3
Lung cancer
#NCT05170204
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
ALK
Systemic Treatment-Naive
EGFR
Immunotherapy
Targeted therapy
Immunotherapy
Targeted therapy
Centre Hospitalier Universitaire de Toulouse (Toulouse)
Hoffmann-La Roche
Phase 3
Lung cancer
#NCT05555732
NSCLC (Non-Small Cell Lung Cancer)
Non-squamous NSCLC
Locally Advanced
Metastatic
PDL1 Negative (< 1%)
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
None
Systemic Treatment-Naive
Immunotherapy
Bispecific T-cell engager antibodies
Antibody Drug Conjugates (ADC)
Immunotherapy
Bispecific T-cell engager antibodies
Antibody Drug Conjugates (ADC)
Centre Hospitalier Universitaire de Montpellier - Site de Saint Eloi (Montpellier)
Daiichi Sankyo
Phase 3
Lung cancer
#NCT05899608
NSCLC (Non-Small Cell Lung Cancer)
Squamous NSCLC
Non-squamous NSCLC
Metastatic
Systemic Treatment-Naive
Centre Hospitalier Universitaire de Montpellier - Site de Saint Eloi (Montpellier)
Summit Therapeutics